Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.17 (
ornithine decarboxylase
)
6,351
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This study evaluates the regulation of casein kinase II (
CK II
) activity in resting B cells induced to enter the cell cycle. The induction of B cell cycle progression PMA and ionomycin results in an oscillatory expression of
CK II
. This kinase activity is also elicited after direct physical interaction between B cells and activated, fixed Th cells, indicating that the increase seen in
CK II
activity is probably associated with the delivery of the competence-inducing signal to resting B cells. The selective inhibition of
ornithine decarboxylase
(
ODC
), the rate-limiting enzyme for polyamine biosynthesis, during PMA and ionomycin-induction of B cell cycle progression, inhibits the expression of
CK II
activity. The addition of polyamines to cytosolic preparations recovered from cells in which
ODC
is inhibited results in the appearance of
CK II
activity, showing that the
ODC
inhibitor does not directly inhibit the kinase. The treatment of B cells with cycloheximide results in the appearance of
CK II
activity within 15 min, and this induction is partially explainable by a cycloheximide-elicited increase in cellular levels of polyamines. The artificial elevation of cellular levels of cAMP simultaneous with the addition of PMA and ionomycin results in a 150 to 200% increase in detectable
CK II
levels, suggesting that the cAMP-dependent signaling cascade may participate during the early regulation of
CK II
. In contrast, the inhibition of protein kinase C does not adversely influence the early expression of
CK II
, while actually enhancing kinase activity by 18 h poststimulation.
...
PMID:Induction and regulation of casein kinase II during B lymphocyte activation. 165 98
